Felix Amissah
Assistant Professor
Pharmacology
Ferris State University
United States of America
Biography
Doctor of Philosophy in Pharmaceutical Sciences (Pharmacology/Toxicology), Florida Agricultural and Mechanical University, Tallahassee, FL, 2013 Master of Philosophy (Pharmacology), Kwame Nkrumah University of Science and Technology Kumasi, Ghana, 2004 Bachelors of Pharmacy (Hons), Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, 2000 Courses Taught PHAR 412 Drug Action 2
Research Interest
My research interest is in the area of cancer therapeutics and interfaces aspects of molecular cancer biology, biochemistry, drug discovery and pharmacology of small molecules against lung cancers with specific mutations that present treatment challenges. Some of the most deadly cancers are due to mutations in the genes of proteins such as K-Ras and overexpression of Cyclooxygenase-2 (COX-2). My work is aimed mainly at finding the molecular "Achilles heels" of these forms of cancers and utilizing natural and synthetic agents for chemoprevention as well as contributing to the development of effective cures.
Publications
-
Amissah F, Duverna R, Aguilar BJ, Poku RA, Kiros GE & Lamango NS. Polyisoprenylated methylated protein methyl esterase overexpression and hyperactivity promotes lung cancer progression. Am J Cancer Res 2014; 4(2), 116-134.
-
Poku RA, Amissah F, Duverna R, Aguilar BJ, Kiros GE & Lamango NS. Polyisoprenylated methylated protein methyl esterase as a putative drug target for androgen-insensitive prostate cancer.ecancer2014, 8:459
-
Nkembo, A., Ntantie, E., Salako, O., Amissah, F., Poku, R., Latinwo, L., & Lamango, N. (2016). The anti-angiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget, 5. 2016 Sep 8. doi: 0.18632/oncotarget.11908
